| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | VWC1; URG11 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human VWCE |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于VWCE抗体的模拟参考文献示例(基于公开领域知识框架生成，实际文献需通过学术数据库验证)：
---
1. **文献名称**: *VWCE Antibody as a Novel Biomarker for Glioblastoma Diagnosis*
**作者**: Smith, A. et al. (2021)
**摘要**: 本研究验证了VWCE抗体在胶质母细胞瘤组织中的特异性表达，发现其与肿瘤侵袭性相关，可能成为神经胶质瘤诊断和预后评估的潜在标志物。
2. **文献名称**: *Functional Characterization of VWCE in Extracellular Matrix Remodeling*
**作者**: Zhang, Y. & Lee, J. (2019)
**摘要**: 通过VWCE抗体阻断实验，揭示了VWCE蛋白在细胞外基质重组中的关键作用，并证明其通过调控整合素信号通路影响细胞迁移。
3. **文献名称**: *VWCE Antibody-Based Therapeutic Potential in Metastatic Cancers*
**作者**: García-Ruiz, C. et al. (2023)
**摘要**: 开发了一种靶向VWCE的人源化单克隆抗体，在乳腺癌和结直肠癌小鼠模型中显著抑制了肿瘤转移，机制涉及血管生成调控。
4. **文献名称**: *Cross-Species Reactivity of Commercial VWCE Antibodies*
**作者**: Müller, T. et al. (2018)
**摘要**: 系统性评估了市售VWCE抗体在小鼠、人类和斑马鱼模型中的交叉反应性，发现部分抗体存在非特异性结合问题，为实验设计提供优化建议。
---
注：以上内容为模拟示例，实际文献请通过PubMed、Google Scholar等平台检索关键词如"VWCE antibody"、"von Willebrand factor C and EGF domain-containing protein"进行验证。
**Background of VWCE Antibody**
The VWCE (Von Willebrand Factor Cleaving Enzyme) antibody is primarily associated with the detection and analysis of ADAMTS13. a metalloprotease responsible for cleaving von Willebrand factor (VWF) multimers. ADAMTS13 plays a critical role in regulating blood coagulation by preventing excessive platelet aggregation and microvascular thrombosis. Deficiencies or dysfunction of ADAMTS13. often due to autoimmune inhibitors (autoantibodies), are linked to thrombotic thrombocytopenic purpura (TTP), a life-threatening disorder characterized by microangiopathic hemolytic anemia and thrombocytopenia.
VWCE antibodies, including both autoantibodies against ADAMTS13 and diagnostic antibodies used in assays, are essential in clinical and research settings. Diagnostic antibodies help quantify ADAMTS13 activity or detect inhibitory antibodies in patient plasma, aiding TTP diagnosis and management. Research applications include studying VWF-ADAMTS13 interactions, mechanisms of thrombosis, and autoimmune responses. Therapeutic strategies, such as plasma exchange or immunosuppression, often target these antibodies to restore ADAMTS13 function. The study of VWCE antibodies continues to advance understanding of thrombotic disorders and refine diagnostic and therapeutic approaches.
×
